which have been implicated in late-onset forms of the disease, as well as the phase 2b LUMA study in early-stage Parkinson’s. LIGHTHOUSE will be dropped in order to focus attention on LUMA ...

With over 10 million people affected worldwide, Parkinson's disease is the fastest-growing neurological disorder. More than ...

Akinesia associated with Parkinson's disease is harder to treat because it is a late-stage manifestation that is rarely fully reversible. With that said, treatments are available to improve motor ...

Cerevance has said it plans to move on to late-stage trials of its first-in-class Parkinson's disease drug CVN424 after hitting the mark in a phase 2 proof-of-concept study. The Boston-based ...

Dyskinesia hampers the quality of life for most Parkinson's disease patients following several ... being quite tolerable in late-onset patients. Understanding the pathogenesis of LID has ...

Annovis Bio Inc. (NYSE: ANVS) ("Annovis"), a late-stage clinical drug platform company pioneering transformative therapies ...

Annovis made significant progress by advancing the buntanetap program, successfully completing two clinical trials—Phase 2/3 AD and Phase 3 PD. Both studies yielded promising results, reinforcing ...

MeiraGTx (Nasdaq: MGTX) has entered into a strategic partnership with artificial intelligence firm Hologen to accelerate the ...

In fact, many scientists consider these two conditions to be the same disease but with different starting places in the brain. In Parkinson’s dementia the movement symptoms are the first to show ...